The Pharma Letter3h
Vigil moves into Phase II with Alzheimer's pill
Vigil Neuroscience advances VG-3927, a small molecule TREM2 agonist, into Phase II Alzheimer’s trials in Q3 2025 following ...
Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments
Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3
Vigil Neuroscience Inc. (NASDAQ:VIGL) released data from its completed Phase 1 trial evaluating VG-3927 as a potential ...
Vigil Neuroscience gains as Alzheimer’s drug reaches mid-stage trial
Shares of Vigil Neuroscience (NASDAQ:VIGL) rose ~18% in the premarket on Thursday after the Sanofi (SNY)-backed biotech said that it expects to advance its Alzheimer's candidate VG-3927 into a Phase 2 ...
Vigil likely to land Alzheimer’s deal after today’s data, says Mizuho
Mizuho analyst Graig Suvannavejh says Vigil Neuroscience (VIGL) this morning reported positive top-line P1 data for VG-3927, a novel small ...
BioSpace22h
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves on to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
Optimistic Outlook for Vigil Neuroscience Inc: Promising Phase 1 Results and Strategic Partnership Potential for VG-3927
Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on VIGL stock, giving a Buy rating today.Invest with ...
Vigil Neuroscience gains after early-stage data for Alzheimer’s drug (update)
Vigil Neuroscience (VIGL) stock rises as the Sanofi (SNY)-backed biotech plans to advance its Alzheimer's candidate VG-3927 ...